Overview
- Legend Biotech reported about $597 million in Q1 2026 net trade sales for CARVYKTI, a CAR T therapy for multiple myeloma, up 62% year over year with 8% growth from Q4 2025.
- In the U.S., earlier use drove demand as second- and third-line patients made up 41% of apheresis (the cell-collection step) in Q1, up from 29% a year earlier.
- Outside the U.S., sales rose more than 200% as launches broadened access to 18 markets and more than 300 treatment sites.
- Gross margin fell to 41% due to one-time costs from expanding manufacturing, and the company expects it to recover to above 50% in Q2 as utilization rises.
- Legend advanced in vivo CAR T programs, with BCMA and GPRC5D in Phase I and initial non-Hodgkin’s lymphoma data anticipated this year, which could diversify revenue beyond CARVYKTI.